MRI时代前列腺体积增大男性的最佳前列腺癌诊断路径
该回顾性研究纳入2017至2020年间因PSA升高行多参数MRI且前列腺≥80g并接受活检的338例患者,评估多参数MRI和靶向活检在检出临床显著前列腺癌中的效用。26.3%患者检出临床显著前列腺癌,MRI对无可疑病灶者的阴性预测值为98.8%,靶向活检较标准活检漏诊临床显著前列腺癌的可能性降低超过50%(12.2% vs 28.3%)。
要点
- 对前列腺≥80g男性,MRI排除临床显著前列腺癌的阴性预测值达98.8%。
- PIRADS 4且PSA密度<0.05时阴性预测值为78.9%,PIRADS 5且PSA密度≥0.15时阳性预测值为90.5%。
- 靶向活检较标准活检漏诊临床显著前列腺癌的可能性降低超过50%(12.2% vs 28.3%)。
核心结论
- 对于前列腺体积较大者,MRI对临床显著前列腺癌的预测性较低,但可有效排除恶性病变。
- PSA密度能更好地指导PIRADS 4和5病灶的活检决策。
- 靶向活检尤其是MRI引导下原位活检在前列腺体积增大中可能具有显著作用。
研究设计与样本
- 回顾性综述2017年至2020年间因PSA升高行多参数MRI的病例资料。
- 纳入前列腺≥80g且接受活检的患者,共338例。
- 临床显著前列腺癌定义为分级分组≥2。
主要发现
- 338例中89例(26.3%)检出临床显著前列腺癌。
- MRI对临床显著前列腺癌的阳性预测值:PIRADS 4为26.5%,PIRADS 5为73.5%。
- MRI无可疑病灶者的阴性预测值为98.8%。
- PIRADS 4病灶在PSA密度<0.05时阴性预测值为78.9%,PIRADS 5病灶在PSA密度≥0.15时阳性预测值为90.5%。
- 靶向活检较标准活检漏诊临床显著前列腺癌的可能性降低超过50%(12.2% vs 28.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate utilities of multiparametric MRI and targeted biopsy to detect clinically significant prostate cancer in men with prostatomegaly. MATERIALS AND METHODS: We conducted a retrospective review of multiparametric MRI obtained for elevated PSA between 2017 and 2020. We selected patients with prostates ≥80 g who had undergone biopsy. Clinically significant prostate cancer was defined as grade group ≥2. Predictive and logistic regression analyses quantified impacts of diagnostic components. RESULTS: A total of 338 patients met inclusion criteria: 89 (26.3%) had clinically significant prostate cancer. On MRI, positive predictive value for clinically significant prostate cancer was 26.5% for PIRADS 4% and 73.5% for PIRADS 5; negative predictive value for MRI without suspicious lesions was 98.8%. Applying PSA density to MRI yielded a negative predictive value of 78.9% for PIRADS 4 lesions at PSA density <0.05 and a positive predictive value of 90.5% for PIRADS 5 lesions at PSA density ≥0.15. Targeted (versus standard) biopsy reduced likelihood of missing clinically significant prostate cancer by >50% (12.2% vs 28.3%). MRI in-bore biopsies trended towards better accuracy versus MRI-transrectal ultrasound fusion biopsies (75% versus 52%). On logistic regression analyses, MRI improved predictive accuracy (area under the curve 0.91), and PIRADS score demonstrated the strongest association with clinically significant prostate cancer (odds ratio 6.42, P < .001). CONCLUSION: For large prostates, MRI is less predictive of clinically significant prostate cancer but effectively rules out malignancy. PSA density better informs biopsy decisions for PIRADS 4 and 5 lesions. There may be a pronounced role for targeted biopsy, specifically in-bore, in prostatomegaly.
引用
- Gold SA, Goueli R, Mostardeiro TR, et al. Optimal Prostate Cancer Diagnostic Pathways for Men With Prostatomegaly in the MRI Era. Urology. 2023. PMID: 37182648. doi:10.1016/j.urology.2023.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。